Inhibikase Therapeutics (IKT) Receivables - Net (2021 - 2023)

Inhibikase Therapeutics (IKT) has reported Receivables - Net for 3 consecutive years, with $79604.0 the latest figure, recorded in Q2 2023.

• In Q2 2023, Receivables - Net rose 1114.96% year-over-year to $79604.0; the TTM figure through Jun 2023 stood at $79604.0 (up 1114.96% YoY), while the FY2022 annual figure was $39881.0, down 63.79% from the prior year.
• Receivables - Net rose to $79604.0 in Q2 2023 per IKT's latest filing, from $64521.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $586581.0 in Q2 2021 and bottomed at $6552.0 in Q2 2022.
• Historically, Receivables - Net has averaged $149935.4 across 3 years, with a median of $72062.5 in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Net sank 98.88% — and 2023, when it soared 1114.96%.
• Inhibikase Therapeutics' Receivables - Net stood at $110141.0 in 2021, then tumbled by 63.79% to $39881.0 in 2022, then surged by 99.6% to $79604.0 in 2023.
• Business Quant data shows IKT's Receivables - Net at $79604.0 in Q2 2023, $64521.0 in Q1 2023, and $39881.0 in Q4 2022.